These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16513016)

  • 1. Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
    Albertazzi P
    J Br Menopause Soc; 2006 Mar; 12(1):7-11. PubMed ID: 16513016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
    Bateman DN; Chick J; Good AM; Kelly CA; Masterton G
    Eur J Clin Pharmacol; 2004 May; 60(3):221-4. PubMed ID: 15083251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analysis of Randomized Trials.
    Riemma G; Schiattarella A; La Verde M; Zarobbi G; Garzon S; Cucinella G; Calagna G; Labriola D; De Franciscis P
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31480427
    [No Abstract]   [Full Text] [Related]  

  • 5. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms.
    Stearns V
    Treat Endocrinol; 2006; 5(2):83-7. PubMed ID: 16542048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
    Handley AP; Williams M
    J Am Assoc Nurse Pract; 2015 Jan; 27(1):54-61. PubMed ID: 24944075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the clinical efficacy of mirtazapine.
    Benkert O; Muller M; Szegedi A
    Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S23-6. PubMed ID: 12404666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
    Shamseddeen W; Clarke G; Keller MB; Wagner KD; Birmaher B; Emslie GJ; Ryan N; Asarnow JR; Porta G; Brent DA
    J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):29-36. PubMed ID: 22251024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.
    Loprinzi CL; Levitt R; Barton D; Sloan JA; Dakhil SR; Nikcevich DA; Bearden JD; Mailliard JA; Tschetter LK; Fitch TR; Kugler JW
    J Clin Oncol; 2006 Mar; 24(9):1409-14. PubMed ID: 16505409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
    Joffe H; Guthrie KA; LaCroix AZ; Reed SD; Ensrud KE; Manson JE; Newton KM; Freeman EW; Anderson GL; Larson JC; Hunt J; Shifren J; Rexrode KM; Caan B; Sternfeld B; Carpenter JS; Cohen L
    JAMA Intern Med; 2014 Jul; 174(7):1058-66. PubMed ID: 24861828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors.
    Biglia N; Torta R; Roagna R; Maggiorotto F; Cacciari F; Ponzone R; Kubatzki F; Sismondi P
    Maturitas; 2005 Sep; 52(1):78-85. PubMed ID: 16143229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing vasomotor symptoms in women after cancer.
    Pinkerton JV; Santen RJ
    Climacteric; 2019 Dec; 22(6):544-552. PubMed ID: 31081391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for hot flushes in women receiving tamoxifen.
    Bydder SA; Spry NA
    Med J Aust; 2002 Sep; 177(5):266. PubMed ID: 12197825
    [No Abstract]   [Full Text] [Related]  

  • 14. The pharmacological and hormonal therapy of hot flushes in breast cancer survivors.
    Wiśniewska I; Jochymek B; Lenart-Lipińska M; Chabowski M
    Breast Cancer; 2016 Mar; 23(2):178-82. PubMed ID: 26498637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonhormonal agents show promise against hot flashes.
    Gottlieb N
    J Natl Cancer Inst; 2000 Jul; 92(14):1118-20. PubMed ID: 10904081
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial.
    Davari-Tanha F; Soleymani-Farsani M; Asadi M; Shariat M; Shirazi M; Hadizadeh H
    Arch Gynecol Obstet; 2016 May; 293(5):1007-13. PubMed ID: 26437957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine hydrochloride for the treatment of hot flashes.
    Schober CE; Ansani NT
    Ann Pharmacother; 2003 Nov; 37(11):1703-7. PubMed ID: 14565812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of citalopram on climacteric symptoms.
    Kalay AE; Demir B; Haberal A; Kalay M; Kandemir O
    Menopause; 2007; 14(2):223-9. PubMed ID: 17224858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.
    Stearns V; Beebe KL; Iyengar M; Dube E
    JAMA; 2003 Jun; 289(21):2827-34. PubMed ID: 12783913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.
    Stubbs C; Mattingly L; Crawford SA; Wickersham EA; Brockhaus JL; McCarthy LH
    J Okla State Med Assoc; 2017 May; 110(5):272-274. PubMed ID: 28649145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.